Startup | November 29, 2021
ZenOnco.io raises US $ 1.4 mn in seed funding
The funds will be used to scale up existing operations and launch new products
The funds will be used to scale up existing operations and launch new products
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
The interim data combines three mRNAs into one therapy injected directly into the tumour
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Subscribe To Our Newsletter & Stay Updated
